摘要
【目的】观察局部晚期鼻咽癌同步放化疗的近期临床疗效及毒副作用。【方法】对收治的Ⅲ、IVa期鼻咽癌84例，随机分为两组，同步放化疗组（A组）及对照组（B组），每组42例，两组放疗方法相同。治疗组在放疗基础上同步行进TP（PTX＋DDP）方案化疗。[结果]A组原发灶放疗后3个月、6个月的完全缓解率为88．1％、90．5％；颈部淋巴结完全缓解率分别为92．9％、95．2％，均明显高于B组（64．3％，65．0％；66．7％，69．0％），且差异有显著性（P〈0．05）。放化组和对照组1年生存率分别为93．5％和87．8％，两者比较差异无显著性。毒副作用主要为骨髓抑制、消化道反应、放射性口腔炎、放射性皮炎。A组骨髓抑制、胃肠道反应的发生率高于B组（P〈0．05），但经对症治疗均能耐受。【结论】同步放化疗能提高晚期鼻咽癌患者的疗效，但其毒副作用增加，尚可耐受，值得临床推广和应用。
[Objective]To observe the clinical efficacy and toxic and side-effects of concurrent chemoradio- therapy for local advanced nasopharyngeal carcinoma. [Methods] Eighty four cases with stage Ⅲ and Ⅳ a nasopharyngeal carcinoma were randomly divided into concurrent chemoradiotherapy group（group A） and control group（Group B） with 42 cases in each. The method of radiotherapy of two groups was the same. Group A received concurrently radiotherapy and chemotherapy with TP （PTX ＋ DDP） regimen. [Results] The complete remission rates in group A at 3 and 6 months after radiotherapy were 88.1% and 90.5%, respectively for nasopharynx, and 92.9% and 95.2 %, respectively for neck lymph node, which were obviously higher than those in group B, and there was significant difference between two group（ P 〈0.05）. The 1-year survival of group A and group B were 93. 5 and 87. 8%, respectively, but there was no significant difference between two groups. The major toxic and side effects were myelosuppression, gastrointestinal reactions, acute radiation stomatitis and radiodermatitis. The incidence of myelosuppression and gastrointestinal reactions in group A were higher than those in group B（ P 〈0.05）, but they could be tolerated after symptomatic treatment. [Conclusion] Concurrent radiochemotherapy can improve the therapeutic effect of advanced nasopharyngeal carcinoma. Its toxic and side effects increase, but they can be tolerated. Therefore, it should be extended and used in clinic.
出处
《医学临床研究》
CAS
2011年第1期32-34,共3页
Journal of Clinical Research
